News
It is important to note that Ozempic and blindness are not usually connected, and vision loss is not a commonly reported or an expected side effect of this weight loss drug. However, if you are on ...
ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down the long-term thesis.
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...
New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...
Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.
I know we wanna cheat the system as Americans, we do,” the 53-year-old tells Page Six in an exclusive interview.
Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...
For patients with a body mass index (BMI) of 70 or higher, metabolic surgery is a highly effective treatment for this form of ...
Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...
A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...
Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...
Obesity prevalence is rapidly increasing among older adults, posing significant health challenges and emphasizing the need ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results